In vitro diagnostics are medical tests performed on samples taken from the body—such as blood, urine or tissue—using instruments or kits outside the patient to detect disease, measure biomarkers or guide treatment decisions. They matter to investors because sales, regulatory approvals, reimbursement rules and adoption rates drive companies’ revenue and margins much like product launches and consumer demand in other industries; advances can create growth or disruption in healthcare markets.
molecular diagnosticsmedical
Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.
point-of-caremedical
"Point-of-care" refers to the location where immediate decision-making or actions happen, often involving the direct delivery of services or results. In healthcare, it describes tests or treatments performed directly at the patient's side, rather than in a distant laboratory. For investors, understanding "point-of-care" highlights the convenience, speed, and potential growth opportunities of services or products that bring solutions directly to the user or patient.
PCRmedical
PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.
U.S. Food and Drug Administration (FDA)regulatory
The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.
510(k) clearanceregulatory
A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.
CLIA waived statusregulatory
CLIA waived status comes from the U.S. Clinical Laboratory Improvement Amendments and is given to diagnostic tests that are simple to use and carry very low risk of incorrect results. For investors, that status matters because it lets tests be sold and run in many places like pharmacies or doctor's offices with minimal regulation, which can speed adoption, cut operational costs and broaden the market—think of it like a product earning a basic safety stamp that opens many retail outlets.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
CAMBRIDGE, England--(BUSINESS WIRE)--
TTP today announced the acquisition by QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group.
Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular testing platform capable of delivering PCR results in minutes.
“At TTP, we identified the opportunity for ultra-fast thermal cycling to unlock the real potential of PCR at the point-of-care,” said Dr Andrew Baker-Campbell, Chair and founding CEO of LEX Diagnostics. “That insight led our scientists and engineers to invent the core technology behind LEX Diagnostics, and TTP spun out the company to bring lab-quality PCR results to clinicians in minutes.”
In February 2026, LEX Diagnostics received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA waived status for its VELO system, which provides lab-quality results of Flu A, Flu B and COVID-19 directly from a swab sample. With positive results available in as little as 6 minutes and negative results in under 10 minutes, the system is designed to support faster diagnosis and more immediate clinical decisions by bringing high-quality molecular PCR testing closer to patients.
“LEX Diagnostics is a great example of how TTP turns breakthrough science into valuable new businesses. We have a long history of partnering with industry to incubate technologies from first principles and scaling them into impactful companies,” said Dr Sam Hyde, CEO of TTP Group. “This acquisition demonstrates the strength of that model and we’re proud to see LEX Diagnostics and the team delivering meaningful advances in patient care, achieving this important milestone and look forward to their continued progress within QuidelOrtho.”
About TTP Group
TTP Group is an independent technology company where scientists and engineers partner with ambitious clients to invent, design, and engineer breakthrough technologies and products that meet real-world needs and make a meaningful impact. Working across sectors including healthcare, medtech, life sciences, communications, defence and industrials, TTP combines deep technical expertise with commercial insight to turn complex challenges into successful products. Alongside client work, TTP has a strong track record of creating and scaling spin-out companies, taking innovations from initial concept through to market adoption and successful exit.
About LEX Diagnostics
LEX Diagnostics is a molecular diagnostics company focused on advancing point-of-care testing through its ultra-fast platform. Founded in 2020 as a spin-out from TTP Group, it has developed proprietary thermal cycling technology enabling rapid, highly sensitive molecular testing. Its VELO system brings PCR-level accuracy to urgent care centres, physician office laboratories and pharmacies, delivering results in minutes and supporting faster diagnosis and treatment decisions. In February 2026, LEX Diagnostics received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA waived status for its VELO system.
